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PhosphorylationSULT4A1 is a cytosolic sulfotransferase that shares little homology with other human sulfotransferases but is
highly conserved between species. It is found in neurons located in several regions of the brain. Recently, the
stability of SULT4A1 was shown to be regulated by Pin1, a peptidyl-prolyl cis-trans isomerase implicated in
several neurodegenerative diseases. Since Pin1 binds preferentially to phosphoproteins, these ﬁndings
suggested that SULT4A1 is post-translationally modiﬁed. In this study, we show that the Thr11 residue of
SULT4A1, which is involved in Pin1 binding is phosphorylated. MEK inhibition was shown to abolish Pin1
mediated degradation of SULT4A1 while in vitro phosphorylation assays using alanine substitution mutants of
SULT4A1 demonstrated phosphorylation of Thr11 by ERK1. We also show that dephosphorylation was
catalyzed by the protein phosphatase 2A. The PP2A regulatory subunit, Bβ was identiﬁed from a yeast-2-
hybrid screen of human brain cDNA as a SULT4A1 interacting protein. This was further conﬁrmed by GST pull-
downs and immunoprecipitation. Other members of the B subunit (α δ γ) did not interact with SULT4A1.
Taken together, these studies indicate that SULT4A1 stability is regulated by post-translational modiﬁcation
that involves the ERK pathway and PP2A. The phosphorylation of SULT4A1 allows interaction with Pin1,
which then promotes degradation of the sulfotransferase., protein phosphatase 2A; HA,
K, mitogen activated protein
es, University of Queensland,
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Sulfotransferase 4A1 (SULT4A1) is a brain speciﬁc cytosolic
sulfotransferase that has little sequence homology with other
human SULTs (b40%) and yet is highly conserved between species
(N98%) [1]. Interest in this protein was stimulated by several recent
studies linking polymorphisms upstream of the SULT4A1 coding
sequence with schizophrenia susceptibility [2,3]. It has also been
associated with intercranial ependymoma, a common CNS tumor in
children [4]. SULT4A1 is up-regulated in the liver following ventro-
medial hypothalamic lesions, suggesting that SULT4A1 expression can
occur outside the brain [5]. This is supported by a recent ﬁnding in
germinal centre B cells where the SULT4A1 gene clusters with a group
of axon growth and guidance genes [6]. Interestingly, SULT4A1 exons
show a very low rate of synonymous or non-synonymous mutations
[7], and has the lowest overall mutation rate amongst all of the known
human sulfotransferases [8].
Recently, we reported that SULT4A1 is a substrate for the peptidyl-
prolyl cis-trans isomerase Pin1, which bound to SULT4A1 through two
Thr-Pro motifs located in the N-terminus of the protein [9]. Theinteraction of Pin1 with SULT4A1 resulted in the rapid degradation of
the sulfotransferase, which was prevented by pretreatment with
okadaic acid. Because Pin1 binds preferentially to phosphor-Thr-Pro
motifs, these results suggested that SULT4A1 must undergo post-
translational modiﬁcation.
In this study, we have investigated the phosphorylation and
dephosphorylation of human SULT4A1. The results show that ERK1 is
capable of phosphorylating SULT4A1 at the Thr11 Pin1 binding
domain. We also demonstrated that SULT4A1 was dephosphorylated
by the serine/threonine phosphatase PP2A. The results provide a
molecular mechanism for the regulation of SULT4A1 stability in cells.
2. Materials and methods
2.1. Plasmids and constructs
The generation of the pGBKT7-SULT4A1, HA tagged pHM6-
SULT4A1, pFLAG-CMV-7.1-SULT4A1 and FLAG tagged SULT4A1
mutants T8A, Thr11A and Thr8/11A constructs have been previously
described [9]. The GST-4A1 construct was generated by PCR
amplifying the SULT4A1 coding region using the following forward
and reverse primers 5′-GATCGGATCCATGGCGGAGAGCGAG-3′; 5′-
CTAGGTCGACTTATAAATAAAAGTCAAACGTG AGGTC-3′ and inserting
it into the BamH1 and Sal1 restriction sites of pGEX6P. To produce the
pGBKT7 (Clontech) and pFLAG-CMV-7.1 (Sigma-Aldrich) constructs,
the coding sequence of PP2A Bβ was PCR ampliﬁed from human
temporal cortex cDNA obtained from the Queensland Brain Bank. The
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into the Nde1 and Pst1 or HindIII and Kpn1 restriction sites (underlined),
respectively. pGBKT7-FP 5′-GATCGACATATGATGGAGGAG GACATTGA-
TACC-3′, pGBKT7-RP 5′-GATCCTGCAGCTAGTTAACCTTGTCCTG-3′ and
pFLAG-FP 5′-GATCAAGCTTATGGAGGAGGACATTGATACCCGC-3′ and
pFLAG-RP 5′-GATCGGTACCCTAGTTAACCTTGTCCTGGAATATATATAG-3′.
The PP2A Bα, Bγ, and Bδ pFLAG-CMV-7.1 constructs were
generated by PCR ampliﬁcation of the full open reading frame
from human brain cDNA using the following primers in which the
EcoR1 and Kpn1 sites were integrated (underlined) for cloning. Bα
FP 5′-GATCGAATTCAATGGCAGGAGCTGG AGGAGGG-3′ and RP 5′-
GATCGGTACCCTAATTCACTTTGTCTTG-3′. Bδ FP 5′-GATCGAATTCA
ATGGCAGGAGCCGGAGGCGGC-3′ and RP 5′-GATCGGTACCCTAGTT-
GATTTTGTCCTGG-3′. Bγ FP 5′-GATCGAATTCAATGGGCGAGGACACG-
GACACG-3′ and RP 5′-GATCGGTACCCTAGTGCA TGTCAGAGTTTAC-3′.
The FLAG-Pin1 construct was generated as described previously [9].
2.2. Cell lines and transfections
Human cervical epithelial HeLa cells (ATCC) were maintained in
DMEM (Dulbecco's modiﬁed eagle medium) supplemented with 5%
fetal bovine serum (FBS) (GIBCO). PC12 rat pheochromocytoma cells
(ATCC)were cultured routinely in RPMI-1640 (GIBCO)with 10% horse
serum (GIBCO) and 5% FBS. Human neuroblastoma IMR-32 cells
(ATCC) were maintained in RPMI-1640 supplemented with 5% FBS.
Total transfected DNAwas held constant by addition of empty control
plasmid. For protein stability and co-immunoprecipitation studies,
total transfected DNA was 3 μg and 2 μg, respectively. Plasmid DNA
was transfected using LipofectAMINE 2000 reagent (Invitrogen)
according to the manufacturer's instructions.
2.3. Co-immunoprecipitation (Co-IP) and pull-down experiments
Transfected cells were washed in phosphate buffered saline (PBS)
and whole cell extracts were prepared using NP-40 lysis buffer (1%
Nonidet P-40, 50 mM Tris [pH 8.0], 150 mM NaCl, and protease
inhibitor cocktail (Roche)). Lysates were cleared by centrifugation at
14,000g for 10 min at 4 °C following incubation in lysis buffer for
15 min on ice. Co-IP samples were incubated with or without rabbit
anti-HA antibody (Sigma-Aldrich) for 2 h at 4 °C after which protein A
sepharose beads (Sigma-Aldrich) were added and the samples
incubated for a further 1 h at 4 °C. For pull-down experiments,
recombinant GST-tagged proteins were expressed in Escherichia coli
strain BL21-Codon Plus (DE3)-RIL (Stratagene) with 0.1 mM Isopro-
pyl β-D-1-thiogalactopyranoside (Sigma-Aldrich) at 37 °C. Bacterial
cells were harvested and lysed in NP-40 lysis buffer on ice for 15 min.
Lysates were cleared by centrifugation at 14,000g for 10 min at 4 °C.
Expressed GST or GST-SULT4A1 was puriﬁed using glutathione
Sepharose 4B (GE Healthcare Bio-Sciences). Cell lysates were
incubated with 10 μg of glutathione Sepharose bound GST or GST-
SULT4A1 for 4 h at 4 °C. For both Co-IP and pull-down samples, beads
were washed 3× with wash buffer (0.5% Nonidet P-40, 50 mM Tris
[pH 8.0], 150 mM NaCl) followed by suspension in SDS loading buffer.
Samples were separated using SDS-PAGE, transferred to nitrocellulose
membrane and immunoblotted with mouse anti-FLAG M2 horse
radish peroxidase (HRP) conjugated primary antibody (Sigma-
Aldrich). To validate HA-protein pull-down, blots were incubated
with mouse anti-HA antibody followed by anti-mouse HRP conjugat-
ed secondary IgG (GE Healthcare Bio-Sciences). Protein bands were
visualized with immunstar (Bio-Rad) as per manufacturer's
instructions.
2.4. Protein stability
Transfected cells were incubated with 10 μg/ml cycloheximide
(Sigma-Aldrich) 24 h after transfection and collected at the indicatedtime points. For inhibitor treatment, cells were incubated with the
following protein kinase inhibitors: H-89 (10 μM),ML3163 (10 μM) or
SL327 (20 μM), or solvent vehicle for 4 h prior to the treatment with
cycloheximide. After 4 h, the treated cells were washed in PBS and
removed from wells by scraping in NP-40 lysis buffer. Lysates were
cleared by centrifugation at 14,000g for 10 min at 4 °C following
incubation in lysis buffer for 15 min on ice. Total protein was deter-
mined by the method of Bradford (Bio-Rad) using BSA as a standard.
An equal quantity of protein from each sample was subjected to SDS-
PAGE, transferred to nitrocellulose membrane and immunoblotted
with mouse anti-FLAG M2 HRP conjugated primary antibody (Sigma-
Aldrich) and mouse anti-tubulin primary antibody (Calbiochem)
followed by anti-mouse HRP conjugated secondary IgG (GE Health-
care Bio-Sciences). Protein bands were visualized with immunstar
(Bio-Rad) as per manufacturer's instructions. Densitometry was
performed using Quantity One Software Version 4.5.
2.5. In cell labeling with [32P] orthophosphate
SULT4A1 transfected HeLa and IMR-32 cells were labeled 24 h post
transfection. Essentially, cells were washed with TBS followed by
incubation for 1 h in phosphate-free DMEM supplemented with 5%
dialyzed fetal bovine serum (Invitrogen). To label phosphorylated
proteins, cells were incubated with 150 μCi of [32P] orthophosphate/
well for 2 h. Cell lysates were prepared and SULT4A1 was immuno-
precipitated as described above using either rabbit anti-SULT4A1
(Proteintech) or mouse anti-FLAG M2 HRP conjugated antibodies.
Immunoprecipitated protein was eluted and separated by SDS-PAGE
and following autoradiograph analysis, the electrophoresed proteins
were transferred to nitrocellulose and immunoblotted with either
rabbit anti-SULT4A1 or mouse anti-FLAG M2 HRP conjugated primary
antibody to detect total SULT4A1 protein loaded. Protein bands were
visualized and quantiﬁed as described above.
2.6. Dephosphorylation assay
[32P] labeled cells were washed with PBS and lysed by incubation
on ice for 15 min with NP-40 (without phosphatase inhibitors) or
PP2A lysis buffer (20 mM Hepes pH 7, 1 mM DTT, 7 mM MgCl2)
containing protease inhibitor cocktail (Roche). Cell lysates were
cleared as described previously followed by protein determination. An
equal quantity of protein from each sample was incubated with either
20 U/ml of calf intestinal alkaline phosphatase (CIP) (New England
Biolabs) or 0.1U recombinant PP2AAC (Millipore) for 30 min at 30 °C.
Samples were then immunoprecipitated and analyzed as described
above.
2.7. Protein kinase assay
FLAG tagged SULT4A1 was expressed in the HeLa cell line and
equal amounts of total protein was immunoprecipitated as described
previously. Kinase reactions were carried out in a total volume of 30 μl
of kinase buffer (5 mM MOPS pH 7.2, 2.5 mM β-glycerophosphate,
1 mM EGTA, 0.4 mM EDTA, 5 mM MgCl2, 0.05 mM DTT) containing
10 μCi of [γ-32P] ATP, 25 μM ATP and 100 ng activated ERK1
(Cell Signaling Technology). Reactions were initiated by the addition
of [γ-32P] ATP and incubated at 30 °C for 30 min before stopping
the reaction by the addition of SDS loading buffer. The immunopre-
cipitated protein was separated by SDS-PAGE and resolved using
autoradiography.
2.8. Yeast-2-hybrid screen
The screen of a human brain cDNA librarywith full length SULT4A1
as bait has been described elsewhere [9]. Brieﬂy, positive clones were
selected for on Leu−, Trp−, His−, and Ade− solid medium and then
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puriﬁed from E. coli and sequenced.
3. Results
3.1. Post-translational modiﬁcation of SULT4A1 by phosphorylation
Our previous ﬁndings illustrating the regulation of SULT4A1 by Pin1
were observed in the HeLa cell line. Initially, therefore, HeLa cells
transfected with FLAG tagged SULT4A1, or empty vector, were labeled
with [32P] orthophosphate following which SULT4A1 protein was
immunoprecipitated and subjected to SDS-PAGE (Fig. 1A). A single
band of radioactivity with a molecular weight of approximately 38 kDa
(representing the protein plus the FLAG tag) was seen in the SULT4A1
transfected cells but not in those transfected with empty vector. We
next compared this to the phosphorylation of SULT4A1 in neuronalFig. 1. In vivo [32P] labeling of SULT4A1. A, HeLa cells were transfected with FLAG-SULT4A1 or
were collected 2 h after incubation followed by immunoprecipitation with anti-FLAG antibo
determined by autoradiography. B, [32P] SULT4A1 is dephosphorylated by calf intestinal alk
PC12 and transfected cells were labeled with [32P] orthophosphate for 2 h followed by cell l
NaF, 1 mM Na3VO4 10 mM β-glycerophosphate) or with 10 U/ml (CIP) for 30 min. Samples w
(PC12) and the resulting proteins were analyzed by SDS-PAGE and autoradiography (uppe
panels). C, Phosphorylation of SULT4A1 is augmented by okadaic acid treatment. HeLa and
treated with or without okadaic acid (100 nM) during labeling with [32P] orthophosphate
antibody (HeLa and IMR-32) or anti-SULT4A1 (PC12). The bound proteins were analyzed by S
determined by Western blot (lower panels).models. Human neuroblastoma IMR-32 cells were transfected with
FLAG-SULT4A1 and radiolabeled with [32P] orthophosphate along with
rat pheochromocytoma PC12 cells, which constitutively express
SULT4A1. Fig. 1B shows a radiolabeled immunoprecipitated SULT4A1
band in all three cell lines tested. Moreover, treatment with calf
intestinal alkaline phosphatase resulted in the loss of radiolabeled
protein. These results demonstrate phosphorylation of both exogenous
and endogenous SULT4A1 protein.
Okadaic acid, a relatively speciﬁc serine/threonine protein phos-
phatase PP2A inhibitor, abolishes Pin1-dependent destabilization of
SULT4A1 [9]. To test the effect of this inhibitor in our neuronalmodels,
PC12 and SULT4A1-transfected IMR-32 cells were labeled with [32P]
orthophosphate in the presence or absence of okadaic acid. The results
show an increase in the phosphorylation state of SULT4A1 in the
presence of okadaic acid (Fig. 1C). These results are in accordance
with our previous ﬁndings and demonstrate that ser/thr residues areempty vector and labeled with [32P] orthophosphate 24 h post-transfection. Cell lysates
dy. The bound protein was subjected to SDS-PAGE and SULT4A1 phosphorylation was
aline phosphatase (CIP). HeLa and IMR-32 cells were transfected with FLAG-SULT4A1.
ysate collection in lysis buffer and treatment with either phosphatase inhibitors (5 mM
ere immunoprecipitated with anti-FLAG antibody (HeLa and IMR-32) or anti-SULT4A1
r panels). Total immunoprecipitated SULT4A1 was determined by Western blot (lower
IMR-32 cells were transfected with FLAG-SULT4A1. PC12 and transfected cells were
for 2 h. Cell lysates were collected and samples immunoprecipitated with anti-FLAG
DS-PAGE and autoradiography (upper panels). Total immunoprecipitated SULT4A1 was
Fig. 2. Thr8 and Thr11 contribute to SULT4A1 phosphorylation. A, Lysates from [32P]-
labeled HeLa and IMR-32 cells transfected with wild-type (WT) or T8/11A mutant
SULT4A1 were immunoprecipitated with anti-FLAG antibody. The bound protein was
subjected to SDS-PAGE and phosphorylation was determined by autoradiography
(upper panel). Total immunoprecipitated SULT4A1 was determined by Western blot
(lower panel). B, IMR-32 cells were transfected with FLAG-SULT4A1 mutant T8/11A.
Cells were treated with or without okadaic acid (100 nM) and labeled with [32P]
orthophosphate for 2 h. Samples were immunoprecipitated with anti-FLAG antibody
and analyzed by SDS-PAGE and autoradiography (upper panels). Total immunopreci-
pitated SULT4A1 was determined by Western blot (lower panels).
Fig. 3. ERK1 directly phosphorylates SULT4A1 A, Immunoprecipitated FLAG-SULT4A1 was in
on a SDS-PAGE gel and analyzed by autoradiography (upper panel). Total immunoprecipita
SULT4A1 Thr11 but not Thr8. HeLa cells were transfected with FLAG-SULT4A1, FLAG-SULT4
post-transfection and SULT4A1 was immunoprecipitated with anti-FLAG antibody. Bound S
mixtures were analyzed by SDS-PAGE followed by autoradiography (upper panel). Total im
SULT4A1 was expressed in HeLa cells along with FLAG-Pin1 for 24 h following which the cell
(10 μg/ml) for a further 4 h. Cell lysates were collected and SULT4A1 levels were quantiﬁe
monitored using anti-tubulin antibody (right panels).
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phosphatase involved in their dephosphorylation.
The threonine residues at positions 8 and 11 in SULT4A1 (Thr8,
Thr11) are part of two Pin1 binding motifs (Thr-Pro) and mutation of
either abolishes Pin1 binding [9]. Since Pin1 preferentially recognises
phosphorylated Ser/Thr-Pro motifs, both threonines were mutated to
alanines and examined for phosphorylation. Fig. 2A shows a marked
decrease in the intensity of the phosphorylated band for the double
mutant compared to wild type SULT4A1 in both HeLa and IMR-32 cells.
However, the double mutant was still phosphorylated to some extent
suggesting that SULT4A1 is phosphorylated at other ser/thr residues. To
test this, IMR-32 cells were transfected with the SULT4A1 double
mutant and treated with and without okadaic acid in the presence of
[32P] orthophosphate. An increase in the phosphorylation of SUL-
T4A1T8/11A was observed with the inhibitor indicating that other ser/
thr residues in SULT4A1 can undergo phosphorylation (Fig. 2B).
3.2. ERK1 phosphorylates Thr11 of SULT4A1
Pin1 substrates can be phosphorylated by a range of proline-
directed kinases. However, ERK1/2 has been most widely reported
and has been shown to phosphorylate the Pin1 binding domain in c-
Myc [10], RNA polymerase II [11], BimEL [12], cyclin D1 [13], c-Jun [14]
and Cdc25 [15]. To test whether ERK1 could directly phosphorylate
SULT4A1, recombinant activated ERK1 was incubated with immuno-
precipitated SULT4A1 and [γ-32P] ATP. The precipitated protein was
then resolved by SDS-PAGE and subjected to autoradiography
(Fig. 3A). ERK1 directly phosphorylated SULT4A1 in vitro. To deter-
mine if this phosphorylation occurred at the Pin1 binding domain,cubated with recombinant active ERK1 and [γ-32P] ATP. The protein was then resolved
ted SULT4A1 was determined by Western blot (lower panel). B, ERK1 phosphorylates
A1T8A, FLAG-SULT4A1T11A or FLAG-SULT4A1T8/11A. Cell lysates were collected at 24 h
ULT4A1 was then incubated with recombinant active ERK1 and [γ-32P] ATP. Reactions
munoprecipitated SULT4A1 was determined by Western blot (lower panel). C, FLAG-
s were treated with the kinase inhibitors for 4 h prior to incubation with cycloheximide
d by Western blotting using an anti-FLAG antibody (left panels). Protein loading was
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ERK1 was determined (Fig. 3B). ERK1 phosphorylated Thr11 but not
Thr8 since a band was evident with the Thr8 mutant protein but not
for either the Thr11 or Thr8/11 mutants. These results also suggest that
ERK1/2 is not responsible for phosphorylation of sites outside of the
Pin1 binding domain as no phosphorylation was evident for the
double mutant (Fig. 3B, last lane).
Since Pin1 promotes the rapid degradation of SULT4A1 [9],
inhibition of SULT4A1 phosphorylation should stabilize the protein.
To test this, HeLa cells were transfected with both SULT4A1 and Pin1
and treated with MEK1/2 inhibitor (SL327) in the presence of
cycloheximide for 4 h. Inhibition of MEK prevents downstream
activation of ERK. In the absence of inhibitor, approximately 40% of
the SULT4A1 protein disappeared over 4 h (Fig. 3C, upper panel),
which is consistent with our previous results [9]. The MEK1/2
inhibitor prevented SULT4A1 degradation whereas inhibitors of two
other proline-directed kinases (p38 MAPK and CK1) had no effect.
Taken together, these results suggest that ERK1 is involved in the
post-translational regulation of SULT4A1.
3.3. SULT4A1 is dephosphorylated by PP2A
HeLa cells were transfected with FLAG tagged SULT4A1 and
subsequently labeled with [32P] orthophosphate. The [32P]-labeled
SULT4A1 protein was immunoprecipitated, and incubated with or
without constitutively active recombinant PP2A A/C dimer (PP2AAC).
The phosphatase was able to completely dephosphorylate SULT4A1Fig. 4. PP2A dephosphorylates SULT4A1. A, PP2A dephosphorylation of SULT4A1. HeLa cells
transfection. Cell lysates were collected 2 h after [32P] addition and incubated with PP2A A/
with anti-FLAG antibody and the bound proteins subjected to SDS-PAGE and autoradiograph
(lower panel). B, Pull-down studies with FLAG-PP2A Bβ and SULT4A1. Cell lysates prepared
alone or GST-SULT4A1. Bound proteins were analyzed byWestern blotting with anti-FLAG an
C, In vivo immunoprecipitation of FLAG-PP2A Bβ and SULT4A1. HeLa cells were transfected w
immunoprecipitated with anti-HA antibody. Samples were analyzed by Western blottin
expression of each protein in the cell extracts. In the absence of anti-HA antibody, no immun
blot) and PP2AB (upper blot) were pulled down. As controls, cells were transfected with o
proteins were expressed alone.(Fig. 4A). Moreover, the effect of PP2AAC was attenuated by okadaic
acid demonstrating the direct dephosphorylation of SULT4A1 by
PP2A. Immunoblotting with anti-FLAG antibody showed that the level
of immunoprecipitated SULT4A1 was equivalent for each condition
(Fig. 4A, lower panel).
3.4. PP2A Bβ subunit is a binding partner of SULT4A1
PP2A exists as a heterotrimer consisting of the ubiquitously ex-
pressed structural (A) and catalytic (C) subunits with one of a variety of
regulatory subunits (B) that are often expressed in a cell- and tissue-
speciﬁc manner [16]. A yeast-2-hybrid screenwith SULT4A1 as bait and
a human brain cDNA library as preywas performed to identify potential
binding partners for the sulfotransferase. This screen identiﬁed Pin1 as
an interacting protein, which has been reported elsewhere [9]. In the
same screen, the regulatory subunit PP2A Bβ was identiﬁed. The
binding of the PP2A Bβ to SULT4A1was conﬁrmed by in vitro pull-down
experiments using recombinant GST-SULT4A1 and expressed FLAG-
PP2A Bβ (Fig. 4B). In addition, immunoprecipitation of PP2A Bβ from
HeLa cells transfected with FLAG-PP2A Bβ and HA-SULT4A1 demon-
strated binding in vivo (Fig. 4C).
Although only the PP2A Bβ subunit was identiﬁed in the screen, it
is possible that other B regulatory subunits from within the B (PR55)
family may also associate with SULT4A1. In mammals, the B or PR55
family is encoded by four genes (α, β, γ and δ). We co-expressed HA-
SULT4A1 with each of the subunits tagged with FLAG and then
immunoprecipitated SULT4A1 with anti-HA antibody (Fig. 5). Despitewere transfected with FLAG-SULT4A1 and labeled with [32P] orthophosphate 24 h post-
C dimer in the absence or presence of okadaic acid. SULT4A1 was immunoprecipitated
y (upper panel). Total immunoprecipitated SULT4A1 was determined by Western blot
from FLAG-PP2A Bβ transfected HeLa cells were incubated with 10 μg recombinant GST
tibody. Input (lane 1) demonstrates FLAG-PP2A Bβ expression in transfected HeLa cells.
ith HA-SULT4A1 and FLAG-PP2AB. Cell lysates were collected 24 h post transfection and
g (WB) with anti-FLAG and anti-HA antibodies. Columns under Input demonstrate
oprecipitation was observed. In the presence of anti-HA antibody, both SULT4A1 (lower
nly HA-SULT4A1 or FLAG-PP2AB. No co-immunoprecipitation was observed when the
Fig. 5. Interaction of SULT4A1 withmembers of the PP2A PR55 B subunit family.HA-SULT4A1was co-expressed with each FLAG tagged PP2A PR55 B subunit in HeLa cells. Cell lysates
were collected 24 h later and SULT4A1 was immunoprecipitated with anti-HA antibody. Bound proteins were then detected by Western blotting using anti-FLAG and anti-HA
antibodies. The Input lanes demonstrate the expression of each protein. In the absence of anti-HA antibody, no co-immunoprecipitation of any subunit was evident. No
immunoprecipitation was observed in the absence of HA antibody. Lane 6 shows that only PR55 PP2A Bβ subunit co-immunoprecipitated with SULT4A1.
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SULT4A1 in vivo.
4. Discussion
In the present study, we have shown that the MAP kinase kinase
(MEK) pathway is important for SULT4A1 turnover and that ERK1 is
capable of phosphorylating SULT4A1 at Thr11, which is essential for
Pin1 interaction with the sulfotransferase [9]. In addition, SULT4A1
was dephosphorylated by PP2A and the Bβ subunit is most likely the
major regulatory subunit that binds to SULT4A1.
Inhibition of MEK1/2 was shown to prevent the Pin1-dependent
degradation of SULT4A1. Phosphorylation of MEK1/2 activates ERK1/2
which in turn can activate the 90 kDa ribosomal S6 kinase (RSK)
[17,18], mitogen and stress-activated kinase (MSK) [19] and the
MAPK-interacting kinases (MNKs) [20,21]. However, kinase assays
showed that SULT4A1 can be phosphorylated by recombinant ERK1.
While both Thr8 and Thr11 are required for Pin1 binding to SULT4A1,
only Thr11 was phosphorylated by ERK1 in the present study. Trinidad
et al identiﬁed Thr8 and Thr11 phosphorylation in SULT4A1 isolated
from mouse brain suggesting that Thr8 may be phosphorylated by a
different protein kinase in humans [22].
Other Pin1 substrates have been reported to be primed for Pin1
association via ERK1 phosphorylation including FAK S910 and c-fos
[23,24]. The ERKs are an important subfamily of the MAPK family and
comprises eight different isoforms, ERK1 through to ERK8 [25,26].
ERK1 is expressed in almost all tissues and is activated through its
phosphorylation at Thr202 and Tyr204 by MEK1/2 [27,28]. ERK1
preferentially phosphorylates substrates that contain the consensus
sequence Pro-Xaa-Ser/Thr-Pro, whereby the second Pro residue is
conserved and the ﬁrst Pro residue is less conserved [29]. This motif is
identical to the sequence surrounding Thr11 in SULT4A1 (Thr8-Pro-
Ser-Thr11-Pro). The Raf-MEK-ERK pathway is central to many cellular
functions including proliferation, survival and differentiation. In thebrain, this pathway can be activated by several neurotransmitters and
neurotoxins such as dopamine [30], cocaine [31], amphetamine [32]
and acetylcholine [33].
We have also reported here that the PP2AAC subunit is capable of
dephosphorylating SULT4A1 and we identiﬁed the PP2A regulatory
subunit B (PR55) β as a SULT4A1 associating protein. PP2A is a highly
conserved serine/threonine phosphatase and, although constitutively
expressed, it is particularly prominent in brain, where the amount of
PP2A is the highest of all tissues investigated [34–37]. The PP2AB
regulatory subunits are responsible for the diverse substrate speciﬁcity
and intracellular localization of the functional PP2A holoenzyme (ABC).
There are at least four distinct groups of PP2AB type regulatory subunits
(PP2AB) which include the B (PR55), B' (PR56/ PR61), B''(PR72) and B'''
(PR93/PR110) families, with each family consisting of several members
[38]. Although the four families do not share apparent sequence
similarities, they do share 80% sequence homology within each family
[39–41]. In mammals, the B or PR55 family is encoded by four genes
(α, β, γ, and δ). We found that SULT4A1 only interacted with the Bβ
subunit of theB (PR55) family,which is foundprimarily in thebrain and,
to a lesser extent in the testis, spleen and lung [38,42,43]. It was not
established whether SULT4A1 can associate with B subunits from the
other three PP2A B subunit families (B', B'' and B'''). However our
ﬁndings suggest that theBβ subunit is responsible for the recruitment of
SULT4A1 to the PP2A complex for dephosphorylation.
Pin1 has been shown to promote the degradation of several target
proteins and, for SULT4A1, this occurs via a polyubiquitination-
independent pathway [9]. Degradation also required PP2A activity as
it was inhibited by okadaic acid. From the present study, we propose
that SULT4A1 stability is regulated in a manner somewhat similar to
that for c-myc [44]. The SULT4A1 protein requires phosphorylation
at Thr11, and possibly Thr8, which allows its interaction with Pin1.
Pin1 isomerizes SULT4A1 thus facilitating its dephosphorylation by
the conformation sensitive serine/threonine phosphatase PP2A
and subsequent degradation. Interestingly, recombinant SULT4A1
237D.J. Mitchell et al. / Biochimica et Biophysica Acta 1813 (2011) 231–237analyzed by mass spectrometry is not phosphorylated at either amino
acid (data not shown). Moreover, many previous studies that have
attempted to identify possible SULT4A1 substrates were performed
using recombinant protein. The lack of post-translational modiﬁcation
of SULT4A1 in the bacterial expression system may need to be
considered for future SULT4A1 enzyme activity investigations.
In conclusion, the current study shows that SULT4A1 is regulated
by post-translational modiﬁcation involving ERK1 and PP2A. The
phosphorylation state allows Pin1 to interact with the N-terminus of
SULT4A1 and promote its degradation. It is now important to establish
whether the enzymatic activity of SULT4A1 protein is also dependent
on these modiﬁcations.
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